![]() BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) each use lipid nanoparticles to deliver mRNA that encodes for a pre-fusion stabilized spike glycoprotein immunogen, and both have shown strong protection in clinical trials and real world experience ( 4, 5). Since December 2020, two different mRNA-based COVID-19 vaccines have received regulatory authorization for use in the USA and have been used to immunize millions of Americans ( 1– 3). Differential IgG decay could contribute to differences observed in clinical protection over time between BNT162b2 and mRNA-1273. Similar findings were observed when comparing vaccine-elicited antibodies with steady-state IgG targeting seasonal human coronaviruses. After six months, IgG levels elicited by BNT162b2, but not mRNA-1273, were lower than IgG levels in patients who had been hospitalized with COVID-19 six months earlier. ![]() Age was a significant modifier of IgG levels in recipients of BNT162b2, but not mRNA-1273. Accordingly, the IgG decay curve was steeper for BNT162b2 than mRNA-1273. However, by day 21 and at later time points IgG levels elicited by BNT162b2 were lower than mRNA-1273. IgG levels measured between seven to 20 days after the second vaccination were similar in recipients of BNT162b2 and mRNA-127 and were ~50-fold higher than in recipients of. Of 234 subjects in the vaccine cohort, 114 received BNT162b2, 114 received mRNA-1273 and six received. Age and sex were explored as response modifiers. Using a quantitative assay we studied binding IgG antibodies elicited by BNT162b2, mRNA-1273 or in an employee cohort over a span out to 10 months. Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines. 4Department of Pharmacology, University of Virginia, Charlottesville, VA, United States. ![]() 3Division of Pulmonary and Critical Care, Department of Medicine, University of Virginia, Charlottesville, VA, United States.2Division of Infectious Disease and International Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, United States.1Division of Allergy & Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, VA, United States.Muehling 1, Glenda Canderan 1, Deborah D. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |